Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study

Authors: Bernd Gagel, Patrick Reinartz, Cengiz Demirel, Hans J Kaiser, Michael Zimny, Marc Piroth, Michael Pinkawa, Sven Stanzel, Branka Asadpour, Kurt Hamacher, Heinz H Coenen, Ulrich Buell, Michael J Eble

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Experimental and clinical evidence suggest that hypoxia in solid tumours reduces their sensitivity to conventional treatment modalities modulating response to ionizing radiation or chemotherapeutic agents. The aim of the present study was to show the feasibility of determining radiotherapeutically relevant hypoxia and early tumour response by ([18F] Fluoromisonidazole (FMISO) and [18F]-2-fluoro-2'-deoxyglucose (FDG) PET.

Methods

Eight patients with non-small-cell lung cancer underwent PET scans. Tumour tissue oxygenation was measured with FMISO PET, whereas tumour glucose metabolism was measured with FDG PET. All PET studies were carried out with an ECAT EXACT 922/47® scanner with an axial field of view of 16.2 cm. FMISO PET consisted of one static scan of the relevant region, performed 180 min after intravenous administration of the tracer. The acquisition and reconstruction parameters were as follows: 30 min emission scanning and 4 min transmission scanning with 68-Ge/68-Ga rod sources. The patients were treated with chemotherapy, consisting of 2 cycles of gemcitabine (1200 mg/m2) and vinorelbine (30 mg/m2) followed by concurrent radio- (2.0 Gy/d; total dose 66.0 Gy) and chemotherapy with gemcitabine (300–500 mg/m2) every two weeks. FMISO PET and FDG PET were performed in all patients 3 days before and 14 days after finishing chemotherapy.

Results

FMISO PET allowed for the qualitative and quantitative definition of hypoxic sub-areas which may correspond to a localization of local recurrences. In addition, changes in FMISO and FDG PET measure the early response to therapy, and in this way, may predict freedom from disease, as well as overall survival.

Conclusion

These preliminary results warrant validation in larger trials. If confirmed, several novel treatment strategies may be considered, including the early use of PET to evaluate the effectiveness of the selected therapy.
Appendix
Available only for authorised users
Literature
1.
Chaiken L, Rege S, Hoh C, Choi Y, Jabour B, Juillard G, Hawkins R, Parker R: Positron emission tomography with fluorodeoxyglucose to evaluate tumour response and control after radiation therapy. Int J Radiat Oncol Biol Phys. 1993, 27: 455-464.CrossRefPubMed
2.
Chapman JD, Schneider RF, Urbain JL, Hanks GE: Single-photon emission computed tomography assays for tissue oxygenation. Semin Radiat Oncol. 2001, 11: 47-57. 10.1053/srao.2001.18103.CrossRefPubMed
3.
Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM, Rusch V: Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial. J Clin Oncol. 2003, 21: 428-432. 10.1200/JCO.2003.04.013.CrossRefPubMed
4.
Dunst J, Stadler P, Becker A, Lautenschlager C, Pelz T, Hansgen G, Molls M, Kuhnt T: Tumour volume and tumour hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol. 2003, 179: 521-526. 10.1007/s00066-003-1066-4.CrossRefPubMed
5.
Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Scheiderbauer J, Machulla HJ, Dittmann H, Vonthein R, Bares R: Prognostic of hypoxia imaging with 18F-Misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005, 46: 253-260.PubMed
6.
Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, Ott R: Noninvasive monitoring of tumour metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumour response to fluorouracil. J Clin Oncol. 1996, 14: 700-708.PubMed
7.
Gagel B, Reinartz P, DiMartino E, Zimny M, Pinkawa M, Maneschi P, Stanzel S, Hamacher K, Coenen HH, Westhofen M, Bull U, Eble MJ: PO2 Polarography versus positron emission tomography ([18F] Fluoromisonidazole, [18F]-2-fluoro-2'-deoxyglucose): an appraisal of radiotherapeutic relevant hypoxia. Strahlenther Onkol. 2004, 180: 616-622. 10.1007/s00066-004-1229-y.CrossRefPubMed
8.
Gray LH, Conger AD, Ebert M: The concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953, 26: 638-642.CrossRefPubMed
9.
Höckel M, Schleger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56: 4509-4515.PubMed
10.
Kirkpatrick JP, Cardenas-Navia LI, Dewhirst MW: Predicting the effect of temporal variations in PO2 on tumor radiosensitivity. Int J Radiat Oncol Biol Phys. 2004, 59: 822-833. 10.1016/j.ijrobp.2004.02.015.CrossRefPubMed
11.
Ling CC, Yorke E, Amols H, Mechalakos J, Erdi Y, Leibel S, Rosenzweig K, Jackson A: High-tech will improve radiotherapy of NSCLC: A hypothesis waiting to be validated. Int J Radiat Oncol Biol Phys. 2004, 60: 3-7. 10.1016/j.ijrobp.2004.05.007.CrossRefPubMed
12.
Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL: Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. JClin Oncol. 2003, 21: 1285-1292. 10.1200/JCO.2003.07.054.CrossRef
13.
Minn H, Kangas L, Knuutila V, Paul R, Sipila H: Determination of 2-fluoro-2-deoxy-D-glucose uptake and ATP level for evaluating drug effects in neoplastic cells. Res Exp Med. 1991, 191: 27-35.CrossRef
14.
Misquitta A, Herman S, Winton T: Accuracy of CT in predicting prognosis in patients with non-small cell lung carcinoma after induction chemotherapy [abstract]. Radiology. 1994, 193: 257-
15.
Nagata Y, Yamamoto K, Hiraoka M, Abe M, Takahashi M, Akuta K, Nishimura Y, Jo S, Masunaga S, Kubo S: Monitoring liver tumour therapy with 18[F]FDG positron emission tomography. J Comput Assist Tomogr. 1990, 14: 370-374.CrossRefPubMed
16.
Nunn A, Linder K, Strauss HW: Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995, 22: 265-280. 10.1007/BF01081524.CrossRefPubMed
17.
Overgaard J, Horsman M: Modification of hypoxia-induced radio resistance in tumours by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996, 6: 10-21.CrossRefPubMed
18.
Price P, Jones T: Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer. 1995, 31A: 1924-1927. 10.1016/0959-8049(95)00421-1.CrossRefPubMed
19.
Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA: Radio-labelled fluoromisonidazole as an imaging agent for tumour hypoxia. Int J Radiat Oncol Biol Phys. 1989, 17: 985-991.CrossRefPubMed
20.
Reisser C, Haberkorn U, Dimitrakopoulou-Strauss A, Seifert E, Strauss LG: Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol. 1995, 121: 272-276.CrossRef
21.
Schäfer U, Micke O, Müller SB, Schuller P, Willich N: Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol. 2003, 179: 527-534. 10.1007/s00066-003-1117-x.CrossRefPubMed
22.
Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stuschke M, Thews O, Vaupel P: Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys. 2003, 55: 1358-1362. 10.1016/S0360-3016(03)00012-9.CrossRefPubMed
23.
Vaupel P, Thews O, Mayer A, Hockel S, Hockel M: Oxygenation Status of Gynecological Tumours: What is the Optimal Haemoglobin Level?. Strahlenther Onkol. 2002, 178: 727-731. 10.1007/s00066-002-1081-x.CrossRefPubMed
24.
World Health Organisation: WHO handbook for reporting results of cancer treatment. 1979, WHO Geneva, Switzerland
25.
Zimny M, Schröder W, Wolters S, Cremerius U, Rath W, Buell U: 18-F Fluordeoxyglukose PET beim Ovarialkarzinom: Methodik und erste Ergebnisse. Nuklearmedizin. 1997, 36: 228-233.PubMed
Metadata
Title
[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study
Authors
Bernd Gagel
Patrick Reinartz
Cengiz Demirel
Hans J Kaiser
Michael Zimny
Marc Piroth
Michael Pinkawa
Sven Stanzel
Branka Asadpour
Kurt Hamacher
Heinz H Coenen
Ulrich Buell
Michael J Eble
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-51

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8

Research article

In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model

Research article

Nestin expression in the cell lines derived from glioblastoma multiforme

Research article

An informatics model for tissue banks – Lessons learned from the Cooperative Prostate Cancer Tissue Resource

Research article

Association between dietary fat and skin cancer in an Australian population using case-control and cohort study designs

Research article

Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits